



**Vivimed**

Date:13/02/2013

To

BSE Limited  
Listing Department  
P.J.Towers,Dalal Street,  
Mumbai – 400001

National Stock Exchange of India Ltd  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E),Mumbai – 400051

**NSE- Symbol: VIVIMEDLAB**

BSE -  Code : 532660

Dear Sir/Madam

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg**

The Board of Directors of the Company at its meeting held on February 13, 2013, inter alia, have resolved and taken note of/approved the following :

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchange, considered and approved the submission of the Unaudited financial results for the Quarter ended December 31,2012 attached herewith;
2. The acquisition of the 100% shareholding, subject to the execution of a shareholders' agreement, related documentation and any other legal and regulatory approvals, of Finoso Pharma Private Limited ("Finoso) a Hyderabad based company, engaged in pharmaceutical development services, for an aggregate consideration of Rs.15,00,00,000 (Rupees fifteen Crores Rupee Only) payable in the form of cash, stock (shares of VIVIMED LABS LTD) and deferred milestone payments.

**ABOUT FINOSO:**

Finoso is a pharmaceutical development services Company, founded by Dr K R Kumar, a reputed technocrat who has built an experienced team, has established a portfolio of global client relationships. The services include formulation development, analytical development, regulatory filings and quality development





**Vivimed**

FINOSO has existing infrastructure at Alexandria Knowledge Park, Turkpally, Hyderabad, which can be leveraged within the full value chain of product development services including formulation dossiers, and out-licensing to support Vivimed Labs' pharmaceutical division strategy both in regulated and semi-regulated markets.

The aggregate acquisition consideration of Rs 15 Crores will comprise, subject to receiving shareholders' approval, execution of documentation and compliance with applicable law: (a) an issue of 142,857 equity shares of Rs 10/- each at a price of Rs 350/- per share to the shareholders of Finoso; and (b) and balance consideration of Rs 10 crores in the form of cash or equivalents in one or more tranches linked to milestones to be agreed.

3. Considered/approved the Notice to take the consent of members for further issue of Shares to Finoso Pharma Private Limited's share holders in Extra-ordinary General Meeting to be held on March 12<sup>th</sup>, 2013 .
4. Accepted the Resignation of Shri. C.Ramakrishna as a Director of the Company w.e.f. closing of business hours on January 11, 2013

The Board has placed on record its appreciation for the valuable contribution made by Shri. C.Ramakrishna in steering the Company on its growth path over the years.

An earnings related presentation including business highlights will be uploaded on the company's website [www.vivimedlabs.com](http://www.vivimedlabs.com)

You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LTD

  
SANTOSH VARALWAR  
MANAGING DIRECTOR & CEO

